Insider Selling: USANA Health Sciences, Inc. (NYSE:USNA) Insider Sells 3,234 Shares of Stock

USANA Health Sciences, Inc. (NYSE:USNA) insider David Mulham Mulham sold 3,234 shares of USANA Health Sciences stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $32.98, for a total value of $106,657.32. Following the sale, the insider now owns 12,775 shares of the company’s stock, valued at approximately $421,319.50. This trade represents a 20.20 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

USANA Health Sciences Stock Performance

USNA traded down $0.06 during midday trading on Tuesday, hitting $33.03. The stock had a trading volume of 81,747 shares, compared to its average volume of 174,238. USANA Health Sciences, Inc. has a 1 year low of $27.71 and a 1 year high of $50.32. The business has a fifty day moving average of $32.96 and a 200 day moving average of $36.18. The company has a market cap of $629.46 million, a P/E ratio of 11.67, a price-to-earnings-growth ratio of 0.93 and a beta of 0.98.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.15. The company had revenue of $213.61 million during the quarter, compared to analysts’ expectations of $208.82 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. On average, equities research analysts anticipate that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. R Squared Ltd purchased a new stake in USANA Health Sciences during the 4th quarter valued at about $28,000. Safe Harbor Fiduciary LLC bought a new stake in USANA Health Sciences in the third quarter valued at approximately $30,000. KBC Group NV boosted its stake in shares of USANA Health Sciences by 96.6% during the third quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after purchasing an additional 519 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of USANA Health Sciences in the fourth quarter worth approximately $83,000. Finally, Quantbot Technologies LP purchased a new position in shares of USANA Health Sciences in the fourth quarter worth $132,000. 54.25% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. DA Davidson dropped their target price on shares of USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating for the company in a research report on Thursday, February 27th. Sidoti downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 18th. Finally, StockNews.com lowered shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 14th.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.